



**SciGen Ltd  
and its subsidiaries**

Registration Number: 199805796R

Interim Financial Information  
Six months ended 30 June 2009

**Results for Announcement to the Market  
For the Six Months Ended 30 June 2009  
(Previous corresponding period: Six months ended 30 June 2008)**

**Revenue and Net Loss**

		<b>Percentage Change</b>		<b>Amount</b>
		<b>%</b>		<b>US\$'000</b>
Revenue from ordinary activities	Down	25	To	4,466
Loss from ordinary activities after tax attributable to members	Up	66	To	6,245
Net loss for the period attributable to members	Up	66	To	6,245

**Revenue**

Revenue for the period has decreased as compared to the previous period due to the lost of existing market in Vietnam and lower sales in existing markets such as Australia, India and Thailand.

**Net Loss**

The net loss has increased as compared with the previous period mainly due to:

- The provision of US\$2,600,000 for termination package of Mr. Saul A. Mashaal; and
- The write-off of Alpha Inteferon Licences & Human Growth Hormone Technology transfer licences of US\$1,607,000.

**Dividend**

The Company does not propose to pay dividends for the six months ended 30 June 2009.

<b>Contents</b>	<b>Pages</b>
1. Directors' Report	3 – 4
2. Statement by Directors	5
3. Independent Review Report	6 – 7
4. Condensed Consolidated Interim Statement of Financial Position	8
5. Condensed Consolidated Interim Statement of Comprehensive Income	9
6. Condensed Consolidated Interim Statement of Changes in Equity	10
7. Condensed Consolidated Interim Statement of Cash Flows	11
8. Notes to the Interim Financial Information	12 – 18
9. Supplementary Appendix 4D Information	19

## Directors' Report

We are pleased to submit this report to the members of the Company together with the interim financial information for the six months ended 30 June 2009.

### Directors

The directors in office at the date of this report are as follows:

Mr. Kenneth Gross  
 Mr. Adam Wilczega  
 Dr. Marian Gorecki  
 Mr. Waldemar Krzewski  
 Mr. Adam Polonek  
 Dr. Joanna Szymańska-Bulska  
 Mr. Adam Allerhand  
 Mr. Janusz Guy  
 Mr. Marcin Dukaczewski

### Review of Operations

A summary of consolidated revenues and results for the six months by significant geographical segments is set out below:

	Segment Revenue		Segment Results	
	30/6/2009	30/6/2008	30/6/2009	30/6/2008
	US\$'000	US\$'000	US\$'000	US\$'000
Singapore	706	427	596	355
Australia	1,660	1,957	(511)	(487)
India	954	1,534	104	137
Korea	610	698	(52)	158
Thailand	776	931	98	81
Others	466	818	(83)	(66)
Eliminations	(706)	(427)	–	–
	<u>4,466</u>	<u>5,938</u>	152	178
Unallocated revenue less unallocated expenses			<u>(6,429)</u>	<u>(3,981)</u>
Loss from ordinary activities before income tax expense			(6,277)	(3,803)
Income tax expense relating to operating activities			(26)	(2)
Net loss for period			<u>(6,303)</u>	<u>(3,805)</u>

Comments on the operations and the results of those operations are set out below:


The Company's activities in the period under review continued to be focused on the registration, manufacturing, marketing and sales of biopharmaceutical products – namely Human Growth Hormone (Scitropin™), SciGen's 3rd generation Hepatitis B Vaccine (Sci-B-Vac™) and recombinant Human Insulin (SciLin™).

During the six months ended and for the period to-date, registration (or other significant milestones) of products were granted or achieved in the following regions. Existing registrations are noted separately.

The Company achieved the following registrations as at the end of the period in the table below:

<b>Country</b>	<b>Scitropin (Sandoz)</b>	<b>Sci-B-Vac (SciGen – IL)</b>	<b>Sci-Locyte</b>	<b>SciLin (Finished Goods)</b>
Australia	Registered	–	–	–
China	–	–	–	Registered
Hong Kong	–	–	–	Registered
India	Registered	Registered	–	Registered
Indonesia	–	–	–	Registered
Israel	–	Registered	–	–
Pakistan	–	–	–	Registered
Philippines	Registered	–	Registered	Registered
Singapore	Registered	–	–	–
Thailand	–	–	–	Registered
Vietnam	–	–	–	Registered

This report is made in accordance with a resolution of the directors.



Adam Allerhand  
 Chief Executive Officer

**Singapore**  
 14 August 2009

## **Statement by Directors**

In the opinion of the directors,


- (a) the unaudited condensed consolidated interim financial information set out on pages 8 to 18 are drawn up so as to give a true and fair view of the state of affairs of the Group as at 30 June 2009 and of the results, changes in equity and cash flows of the Group for the six months ended on that date in accordance with the provisions of Singapore Financial Reporting Standards FRS 34 *Interim Financial Reporting*; and
- (b) at the date of this statement, having regard to the financial support provided by the holding company and that the holding company has confirmed that it will not demand for settlement of the loans given to the Company within the next twelve months, there are reasonable grounds to believe that the Group will be able to pay its debts as and when they fall due.

The Board of Directors has, on the date of this statement, authorised these unaudited condensed consolidated interim financial information for issue.

On behalf of the Board of Directors



Adam Allerhand  
Chief Executive Officer



Kenneth Gross  
Non-Executive Director

**Singapore**

14 August 2009



**KPMG LLP**  
16 Raffles Quay #22-00  
Hong Leong Building  
Singapore 048581

Telephone +65 6213 3388  
Fax +65 6225 0984  
Internet www.kpmg.com.sg

## **Independent review report**

Members of the Company  
SciGen Ltd

### ***Introduction***

We have reviewed the accompanying condensed consolidated interim statement of financial position of SciGen Ltd and its subsidiaries (the "Group") as at 30 June 2009, and the related condensed consolidated interim statements of income, changes in equity and cash flows for the six months period then ended and certain explanatory notes as set out on pages 8 to 18 (the "Interim Financial Information"). Management is responsible for the preparation and presentation of this Interim Financial Information in accordance with Singapore Financial Reporting Standard ("FRS") 34 *Interim Financial Reporting*. Our responsibility is to express a conclusion on this Interim Financial Information based on our review.

### ***Scope of review***

We conducted our review in accordance with Singapore Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Singapore Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### ***Conclusion***

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Interim Financial Information is not prepared, in all material respects, in accordance with FRS 34 *Interim Financial Reporting*.

### ***Emphasis of matter***

Without qualifying our conclusion, we draw attention to Note 1 to the interim financial information which states that the interim financial information have been prepared on a going concern basis notwithstanding the net loss of US\$6,303,000 and negative operating cash flows of US\$1,290,000 for the six months ended 30 June 2009, and as of that date, the Group had net current liabilities of US\$7,478,000. The Group has also projected to be in a net current liabilities position for at least the next twelve months from the reporting date.



These conditions, along with the other matters set forth in Note 1 of the interim financial information, indicate the existence of a material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern, and, therefore the Group may be unable to realise its assets and discharge its liabilities in the normal course of business.

**KPMG LLP**

**KPMG LLP**  
*Public Accountants and*  
*Certified Public Accountants*

Singapore  
14 August 2009



**Condensed consolidated interim statement of financial position**  
**As at 30 June 2009**

	Note	30/6/2009 US\$'000	31/12/2008 US\$'000
<b>Non-current assets</b>			
Property, plant and equipment	5	52,406	49,119
Intangible assets	6	28,510	29,827
Lease prepayment		1,274	1,299
Investment property		254	249
Long term prepayment		33	226
Deferred tax assets		–	12
		<u>82,477</u>	<u>80,732</u>
<b>Current assets</b>			
Inventories		2,029	1,260
Trade and other receivables		4,350	7,598
Cash and cash equivalents		4,944	6,092
		<u>11,323</u>	<u>14,950</u>
<b>Total assets</b>		<u>93,800</u>	<u>95,682</u>
<b>Equity attributable to equity holders of the Company</b>			
Share capital		42,530	42,530
Reserves		(1,068)	(1,700)
Accumulated losses		(40,596)	(34,351)
		<u>866</u>	<u>6,479</u>
<b>Minority interests</b>		<u>5,880</u>	<u>5,808</u>
<b>Total equity</b>		<u>6,746</u>	<u>12,287</u>
<b>Non-current liabilities</b>			
Trade and other payables		1,888	4,683
Financial liabilities	7	65,474	61,767
		<u>67,362</u>	<u>66,450</u>
<b>Current liabilities</b>			
Trade and other payables		19,540	16,812
Financial liabilities	7	16	7
Current tax payable		136	126
		<u>19,692</u>	<u>16,945</u>
<b>Total liabilities</b>		<u>87,054</u>	<u>83,395</u>
<b>Total equity and liabilities</b>		<u>93,800</u>	<u>95,682</u>

The accompanying notes form an integral part of these interim financial information.

**Condensed consolidated interim statement of comprehensive income**  
**Six months ended 30 June 2009**

	Note	30/6/2009 US\$'000	30/06/2008 US\$'000
Revenue		4,466	5,938
Other income (net)		143	23
Changes in inventories of finished goods		200	354
Purchases		(2,259)	(3,481)
Staff costs		(4,529)	(2,361)
Depreciation of property, plant and equipment		(33)	(28)
Depreciation of investment property		(16)	-
Amortisation of lease prepayment		(23)	(23)
Amortisation of intangible assets		(64)	(73)
Other expenses		(3,671)	(3,202)
<b>Loss from operating activities</b>		<u>(5,786)</u>	<u>(2,853)</u>
Finance income		307	339
Finance expense		(798)	(1,289)
<b>Net finance expense</b>	8	<u>(491)</u>	<u>(950)</u>
<b>Loss from operating activities before income tax</b>	8	<u>(6,277)</u>	<u>(3,803)</u>
Income tax expense		(26)	(2)
<b>Loss for the period</b>		<u>(6,303)</u>	<u>(3,805)</u>
<b>Other comprehensive income</b>			
Exchange differences on translating foreign operations		501	421
<b>Other comprehensive income for the period, net of tax</b>		<u>501</u>	<u>421</u>
<b>Total comprehensive losses for the period</b>		<u>(5,802)</u>	<u>(3,384)</u>
<b>Attributable to:</b>			
Equity holders of the Company		(6,245)	(3,754)
Minority interest		(58)	(51)
<b>Loss for the period</b>		<u>(6,303)</u>	<u>(3,805)</u>
<b>Total comprehensive losses attributable to:</b>			
Equity holders of the Company		(5,744)	(3,333)
Minority interest		(58)	(51)
<b>Total comprehensive losses for the period</b>		<u>(5,802)</u>	<u>(3,384)</u>
<b>Loss per share</b>			
Basic loss per share (cents)	9	(1.14)	(0.68)
Diluted loss per share (cents)	9	<u>(1.14)</u>	<u>(0.68)</u>

Note: There is no tax effect on the component indicated in other comprehensive income.

The accompanying notes form an integral part of these interim financial information.

Condensed consolidated interim statement of changes in equity  
Six months ended 30 June 2009

	Share capital US\$'000	Foreign currency translation reserve US\$'000	Share option reserve US\$'000	Accumulated losses US\$'000	Total attributable to equity holders of the Company US\$'000	Minority interests US\$'000	Total equity US\$'000
At 1 January 2008	42,530	217	914	(26,249)	17,412	3,166	20,578
Total comprehensive income/(loss) for the period	-	421	-	(3,754)	(3,333)	(51)	(3,384)
Contribution by minority shareholders of a subsidiary	-	-	-	-	-	1,747	1,747
Equity-settled share-based payment transactions	-	-	387	-	387	-	387
At 30 June 2008	42,530	638	1,301	(30,003)	14,466	4,862	19,328
At 1 January 2009	42,530	(3,300)	1,600	(34,351)	6,479	5,808	12,287
Total comprehensive income/(loss) for the period	-	501	-	(6,245)	(5,744)	(58)	(5,802)
Contribution by minority shareholders of a subsidiary	-	-	-	-	-	130	130
Equity-settled share-based payment transactions	-	-	131	-	131	-	131
At 30 June 2009	42,530	(2,799)	1,731	(40,596)	866	5,880	6,746

The accompanying notes form an integral part of these interim financial information.

**Condensed consolidated interim statement of cash flows**  
**Six months ended 30 June 2009**

	<b>30/6/2009</b>	<b>30/6/2008</b>
	<b>US\$'000</b>	<b>US\$'000</b>
<b>Operating activities</b>		
Loss for the period	(6,303)	(3,805)
Adjustments for:		
Depreciation of property, plant and equipment	33	28
Depreciation of investment property	16	–
Amortisation of lease prepayment	23	23
Amortisation of intangible assets	64	73
Loss on disposal of plant and equipment	68	18
Intangible assets written-off	1,607	–
Equity-settled share-based payment transactions	131	387
Interest income	(237)	(165)
Interest expenses	798	1,289
Income tax expenses	26	2
	<hr/>	<hr/>
	(3,774)	(2,150)
Changes in working capital:		
Inventories	(769)	30
Trade and other receivables	3,248	(2,122)
Trade and other payables	31	(83)
	<hr/>	<hr/>
<b>Cash used in operations</b>	(1,264)	(4,325)
Income taxes paid	(26)	(2)
	<hr/>	<hr/>
<b>Cash flows from operating activities</b>	(1,290)	(4,327)
<b>Investing activities</b>		
Interest received	16	82
Purchase of property, plant and equipment	(2,855)	(6,739)
Purchase of intangible assets	(357)	(1,799)
	<hr/>	<hr/>
<b>Cash flows from investing activities</b>	(3,196)	(8,456)
<b>Financing activities</b>		
Interest paid	(12)	(28)
Proceeds from bank loan	9	–
Repayment of bank loan	–	(5)
Loans from holding company	3,706	14,000
Capital contribution by minority shareholders of a subsidiary	130	1,747
	<hr/>	<hr/>
<b>Cash flows from financing activities</b>	3,833	15,714
<b>Net (decrease)/increase in cash and cash equivalents</b>	(653)	2,931
Cash and cash equivalents at beginning of the period	6,092	4,912
Effect of exchange rate fluctuations on cash held	(495)	(220)
	<hr/>	<hr/>
<b>Cash and cash equivalents at end of the period</b>	4,944	7,623

The accompanying notes form an integral part of these interim financial information.

## **Notes to the unaudited condensed consolidated interim financial information**

### **1 Going concern**

As at 30 June 2009, the Group had a net loss of US\$6,303,000 and negative operating cash flows of US\$1,290,000 for the six months ended 30 June 2009, and, as of that date, the Group had net current liabilities of US\$7,478,000. The Group has also projected to be in a net current liabilities position for at least the next twelve months from the reporting date.

The directors of the Company consider that it is appropriate for the Company to prepare its interim financial information on a going concern basis as the Company has received an undertaking from the holding company to continue to provide the Group with financial and other support as necessary for the next twelve months to enable the Group to continue as a going concern and to support their operating and investing activities.

#### ***Emphasis of matter***

Owing to the net current liabilities of the Group as at 30 June 2009 and a projected net current liabilities position for at least another twelve months from the reporting date, and if the Group is unable to continue with the necessary funding from the holding company, adjustments would have to be made to the Group's assets to reflect the situation that the assets may need to be realised other than in the normal course of business and at amounts which could differ significantly from the amounts stated in the condensed consolidated statement of financial position of the Group as at 30 June 2009. These are conditions which indicate the existence of a material uncertainty, which may cast significant doubt on the Group's ability to continue as a going concern, and, therefore, the Group may be unable to realise its assets and discharge its liabilities in the normal course of business.

### **2 Summary of significant accounting policies**

#### **Basis of preparation**

The unaudited condensed consolidated interim financial information of SciGen Ltd (the "Company") and its subsidiaries (the "Group") have been prepared on a condensed basis in accordance with Singapore Financial Reporting Standard FRS 34 *Interim Financial Reporting*.

The unaudited condensed consolidated interim financial information, which do not include the full disclosures of the type normally included in a complete set of financial statements, are to be read in conjunction with the last issued financial statements as at 31 December 2008. Amounts are expressed in United States dollars, which is the Company's functional currency and rounded to the nearest thousand, unless stated otherwise.

Accounting policies and methods of computation used in the unaudited condensed consolidated interim financial information are consistent with those applied in the financial statements for the year ended 31 December 2008.

### **3 Adoption of new accounting standards**

For the six months ended 30 June 2009, the Group adopted the following new/revised FRSs which are relevant to its operations:

FRS 1	<i>Presentation of Financial Statements</i>
FRS 23	<i>Borrowing Costs</i>
Amendments to FRS 27	<i>Consolidated and Separate Financial Statements – Cost of an Investment in a Subsidiary, Jointly Controlled Entity or Associate</i>
Amendments to FRS 101	<i>First-time Adoption of Financial Reporting Standards</i>
FRS 108	<i>Operating Segments</i>

The adoption of the above new/revised FRSs which are effective in the new financial period would have no impact on the recognition and measurement of the Group's unaudited condensed consolidated interim financial information.

### **4 Seasonal operations**

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

### **5 Property, plant and equipment**

During the six months ended 30 June 2009, the Group acquired property, plant and equipment and capitalised construction cost of approximately US\$80,000 and US\$2,775,000 (Year ended 31 December 2008: US\$946,000 and US\$17,165,000) respectively.

## 6 Intangible assets

Group	Licences US\$'000	Computer software US\$'000	Development costs US\$'000	Total US\$'000
<b>Cost</b>				
At 1 January 2008	25,299	70	669	26,038
Additions during the year	3,448	–	986	4,434
Translation difference	(4)	–	1	(3)
At 31 December 2008	28,743	70	1,656	30,469
Additions during the period	–	–	357	357
Written off during the period	(1,607)	–	–	(1,607)
Translation difference	(2)	–	(1)	(3)
At 30 June 2009	27,134	70	2,012	29,216
<b>Accumulated amortisation</b>				
At 1 January 2008	497	2	–	499
Amortisation charge for the year	116	27	–	143
At 31 December 2008	613	29	–	642
Amortisation charge for the period	55	9	–	64
At 30 June 2009	668	38	–	706
<b>Carrying amount</b>				
At 1 January 2008	24,802	68	669	25,539
At 31 December 2008	28,130	41	1,656	29,827
At 30 June 2009	26,466	32	2,012	28,510

## 7 Financial liabilities

	30/6/2009 US\$'000	30/06/2008 US\$'000
<b>Non-current</b>		
Secured bank loans	147	124
Loans from holding company	65,327	61,643
	65,474	61,767
<b>Current</b>		
Secured bank loans	16	7
	65,490	61,774

The loans from holding company were made on normal commercial terms and conditions and bear interest at LIBOR 3 months + 1% (31/12/2008: LIBOR 3 months + 1%) per annum. The loans and interests are due for repayment on 31 December 2011.

## 8 Additional disclosure for interim statement of comprehensive income

The following items have been charged or (credited) in arriving at loss for the period:

	30/6/2009 US\$'000	30/06/2008 US\$'000
Share-based payment, included in staff costs	131	387
Loss on disposal of plant and equipment	68	18
Intangible assets written-off	1,607	–
Finance income:		
Interest income received from banks	(16)	(82)
Accretion of finance income on non-current payables	(221)	(83)
	(237)	(165)
Exchange gain	(70)	(174)
	(307)	(339)
Finance expense:		
Interest expense paid to banks	12	28
Interest expense payable to holding company	786	1,261
	798	1,289
Net finance expense recognised in the condensed statement of comprehensive income	491	950

## 9 Loss per share

	30/6/2009 US\$'000	30/6/2008 US\$'000
Basic and diluted loss per share is based on:		
(i) Net loss attributable to ordinary shareholders	(6,303)	(3,754)
Number of shares		
	30/6/2009 (‘000)	30/6/2008 (‘000)
(ii) Weighted average number of ordinary shares at the end of the period	552,270	552,270

For the financial period ended 30 June 2008 and 2009, the options granted to an ex-director was not included in the determination of diluted loss per share of the Group, as the options are considered to be anti-dilutive potential ordinary shares.



## 10

### Operating segments

The Group has 6 reportable segments, as described below, which are the Group's strategic business units. The strategic business units offer different products, and are managed separately because they require different marketing strategies. For each of the strategic business unit, the CEO reviews internal management reports regularly. The following summary describes the operations in each of the Group's reportable segments:

- **Singapore:** The home country of the parent entity which is also the main operating entity. The areas of operation are principally corporate office functions and sales and marketing.
- **Australia, India, Korea, Thailand:** Includes sales and marketing activities of recombinant human growth hormones
- **Others:** Comprises operations carried on in Hong Kong, Philippines, Indonesia, Vietnam and countries in South East Asia

	Singapore	Australia	India	Korea	Thailand	Others	Eliminations	Total	
30/6/2009	30/6/2008	30/6/2009	30/6/2008	30/6/2009	30/6/2008	30/6/2009	30/6/2008	30/6/2009	
US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	
Sales to external customers	-	1,660	954	610	776	466	818	-	4,466
Inter-segment sales	706	427	-	-	-	-	(706)	(427)	-
Total sales revenue	706	1,660	954	610	776	466	818	(427)	4,466
Segment results	596	(511)	104	(52)	98	(83)	(66)	-	152

Unallocated revenue less unallocated expenses	(6,429)	(3,981)
Loss from operating activities before income tax	(6,277)	(3,803)
Income tax expense	(26)	(2)
Loss for the period	(6,303)	(3,805)

## 11 Commitments

Commitments not reflected in the unaudited condensed consolidated interim financial information at the reporting dates are as follows:

### (a) Operating lease commitments

The Group leases a number of offices under operating leases. These leases typically run for an initial period of 1 to 5 years, with an option to renew the lease after that date. Lease payments are usually revised when the leases are renewed to reflect market rentals.

At 30 June 2009, the Group has commitments for future minimum lease payments under non-cancellable operating leases are as follows:

	30/6/2009 US\$'000	31/12/2008 US\$'000
Within 1 year	702	841
After 1 year but within 5 years	356	702
	1,058	1,543

The Group leases out its investment property and the lease typically run for a 1 year, with an option to renew the lease after that date. Lease receipts are usually revised when the lease is renewed to reflect market rentals. Operating lease rentals are receivable as follows:

	30/6/2009 US\$'000	31/12/2008 US\$'000
Within 1 year	6	24
After 1 year but within 5 years	–	4
	6	28

### (b) Capital commitments

	30/6/2009 US\$'000	31/12/2008 US\$'000
Capital expenditure contracted but not provided for in the interim financial information is as follows:		
Acquisition of assets	–	7,292
	–	7,292

## 12 Significant related party transactions

### *Identity of related parties*

For the purpose of the unaudited condensed consolidated interim financial information, parties are considered to be related to the Group if the Group has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.

Remuneration and retirement benefits paid/payable to directors are as follows:

	<b>30/6/2009</b>	<b>30/6/2008</b>
	<b>US\$'000</b>	<b>US\$'000</b>
Income paid or payable, or otherwise made available, to directors by the entities in the Group and the Company and related parties in connection with the management of affairs of the parent entity or its controlled entities (excluding executives of the parent entity who are only directors of wholly-owned subsidiaries)	1,025	726
Termination benefits payable to an ex-director of the Company	2,600	–
	3,625	726

The above remuneration and retirement benefits paid/payable to directors include the termination benefits of US\$2.6 million payable to an ex-director of the Company whose appointment was terminated on 20 April 2009.

During the financial period, other than disclosed elsewhere in the interim financial information, there were the following significant transactions carried out in normal course of business with related parties:

	<b>30/6/2009</b>	<b>30/6/2008</b>
	<b>US\$'000</b>	<b>US\$'000</b>
<b>Holding company</b>		
Purchases of goods	1,261	1,799
	1,261	1,799

### **13 Subsequent events**

On 10 July 2009, the Company and its holding company, Bioton S.A (“Bioton”), entered into an exclusive supply and distribution agreement with Bayer Schering Pharma AG (“Bayer”) for the commercialisation of Bioton’s insulin in the People’s Republic of China.

Following the execution of the above agreement with Bayer, the Company entered into a profit sharing agreement with Bioton. Under the profit sharing agreement, the Company will receive a share of revenues from the agreement with Bayer for a period of 15 years.

## Supplementary Appendix 4D information

### NTA backing

	<b>30/6/2009</b>	<b>31/12/2008</b>
	<b>(cents)</b>	<b>(cents)</b>
Net tangible liabilities backing per ordinary share	(3.94)	(3.18)

### Controlled entities acquired or disposed of

<b>Acquired</b>			
Date control gained	N/A	N/A	N/A
Contribution to profit from ordinary activities after tax in current period, where material	N/A	N/A	N/A
Profit from ordinary activities after tax during the whole of the previous corresponding period, where material	N/A	N/A	N/A
<b>Disposed of</b>			
Date control lost	N/A	N/A	N/A
Contribution to profit from ordinary activities after tax in current period, where material	N/A	N/A	N/A
Profit from ordinary activities after tax during the whole of the previous corresponding period, where material	N/A	N/A	N/A

### Additional dividend/distributions information

There are no dividends or distributions declared or paid during or subsequent to the six months ended 30 June 2009.

### Dividend/distribution reinvestment plans

There are no dividends or distribution reinvestment plans during or subsequent to the six months ended 30 June 2009.

### Associates and Joint Venture entities

There are no additional investments in associates or joint venture entities during the period or subsequent to the six months ended 30 June 2009.

### Foreign Accounting Standards

This six months ended report for the interim reporting period ended 30 June 2009 has been prepared in accordance with Singapore Financial Reporting Standards.